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The respiratory chain of the human malaria parasite Plasmodium
falciparum lacks a canonical protonmotive NADH:ubiquinone
oxidoreductase (Complex I), containing instead a single-subunit,
non-protonmotive NDH2, similar to that found in plant mitochon-
dria, fungi and some bacteria [1,2]. As such, the P. falciparum NDH2
(PfNDH2) presents itself as an attractive anti-malarial chemothe-
rapeutic target, and we have developed a heterologous expression
system for this enzyme in the E. coli NADH dehydrogenase
knockout strain ANN0222 (generously provided by Prof. Thorsten
Friedrich, Freiburg) to facilitate its physicochemical and enzymo-
logical characterisation [3]. PfNDH2 represents a metabolic choke
point in the respiratory chain of P. falciparum mitochondria and is
the focus of a drug discovery programme towards the development
of a novel therapy for uncomplicated malaria. Here we describe a
miniaturised assay for recombinant PfNDH2 with robust assay
performance measures that has been utilised for the high
throughput screening (HTS) of small molecule inhibitors. The
objectives of the HTS were to (i) increase the number of selective
PfNDH2 inhibitors and (ii) to expand the number of inhibitor
chemotypes. At the time of screening, only one proof of concept
molecule, 1-hydroxy-2-dodecyl-4-(1H)quinolone (HDQ), was
known to have PfNDH2 inhibitory activity (IC50=70 nM) [3,4].
This molecule was used to initiate a primary similarity-based
screen of 1000 compounds from a compound collection of 750000
compounds (curated by Biofocus-DPI). A range of chemoinfor-
matics methods and filters were applied to the hits from this initial
phase in order to perform a hit expansion screen on a further about
16000 compounds. The chemoinformatic strategy allowed us to
cover about 16% diversity whilst screening just about 2% of the
compound collection. The HTS resulted in a hit rate of 0.29% and
150 compounds were progressed for potency against PfNDH2. Of
these compounds, 50 were considered active with IC50s ranging
from 100 nM to 40 µM. Currently, seven distinct chemotypes are
being progressed from hit to lead using traditional synthetic
medicinal chemistry strategies.
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Idebenone [2,3-dimethoxy-5-methyl-6(10-hydroxidecyl)-1,4-
benzoquinone] is a synthetic analogue of coenzyme Q10 (CoQ10),
an essential constituent of the mitochondrial electron transport chain
and a powerful antioxidant. Idebenone is also a good electron carrier
in the mitochondrial respiratory chain. Quinones (including idebe-
none) have also been shown to affect the mitochondrial permeability
transition (PT) pore (PTP) a high-conductance inner membrane chan-
nel modulated by the proton electrochemical gradient and by many
signaling molecules. PTP links oxidative stress to cell death and seems
to be involved in Leber's hereditary optic neuropathy (LHON) and
other pathologies of neurological interest. Given these complex ef-
fects of idebenone on cellular bioenergetics we have investigated its
effects on bioenergetics and PTP modulation in intact cells. Our
preliminary results indicate that: (i) idebenone modulates the PTP in
situ through an interaction with NEM-sensitive thiols, with an effect
that can be inhibited by Cyclosporin A (CsA); (ii) DTT prevents the
PTP-inducing effects of idebenone, and promotes electron transfer
from idebenone to complex III of the respiratory chain bypassing the
lack of complex I activity; (iii) in the presence of DTT, idebenone
considerably increases antimycin A-sensitive respiration both in nor-
mal and in RJ206 cells (harboring the 3460/ND1 LHON mutation)
and XTC.UC1 thyroid oncocytoma cells (bearing a disruptive frame-
shift mutation in the MT-ND1 gene which impairs complex I
assembly). The key question of whether idebenone-supported
respiration is used for ATP synthesis is being addressed.
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Treatment with the ω-3 polyunsaturated fatty acids (PUFAs)
docosahexanoic acid (DHA) and eicosapentanoic acid (EPA) exerts
cardioprotective effects in patients, and suppresses Ca2+-induced
opening of the mitochondrial permeability transition pore (MPTP) in
vitro. These effects are associated with increased DHA and EPA and
lower arachidonic acid (ARA) in cardiac phospholipids. ARA is
implicated in inflammation and induction of MPTP opening. While
clinical studies suggest the triglyceride lowering effects of DHA and
EPA are equivalent, there is growing evidence that DHA may be
superior at remodeling mitochondrial phospholipids and preventing
MPTP. Therefore we compared the effects of dietary supplementation
with the ω-3 PUFAs DHA and EPA on cardiac mitochondrial phos-
pholipid fatty acid composition and Ca2+-inducedMPTP opening. Rats
were fed either a control (CTRL) low-fat chow, or a similar diet
supplementedwith either DHA or EPA only at 2.5% of energy intake for
8 weeks. These doses of DHA and EPA are comparable to about 5 g/day
in humans. Cardiacmitochondriawere isolated and analyzed for Ca2+-
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